CORDIS · 602391 · FP7
EPISTOP Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex
Coordinator: INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA (PL)
Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usually present AFTER the seizure onset.EPISTOP is the first prospective study of epileptogenesis in humans, beginning BEFORE seizures and continuing through age 2+ years, permitting detailed analysis of …
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €9.5M awarded to the consortium. The project runs over approximately 5 years from 2013-11-01 to 2018-10-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from PL
see all →- UASEEDs — SEEDS OF BRAVERY: supporting Ukraine’s tech start-up scene and bringing it closer to the EU101104445 · HORIZON · €20.0M
- P4Health — Centre of Excellence for Precise Phenotyping and BioDataBanking101136375 · HORIZON · €15.0M
- Astrocent Plus — Astrocent Plus -- Particle Astrophysics Science and Technology Centre101137080 · HORIZON · €15.0M
- TRIO-VI CoE — Translational Research and Innovation in Ophthalmology Vision - Centre of Excellence101136570 · HORIZON · €15.0M
- QuantERA III — QUANTERA III RIA: COFUND IN QUANTUM TECHNOLOGIES101212998 · HORIZON · €15.0M
- QuantERA II — QuantERA II ERA-NET Cofund in Quantum Technologies101017733 · H2020 · €15.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-IP funding scheme.
- What is the EU contribution?
- The European Commission contributes €9.5M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA (PL).
- What is the project timeline?
- The project runs from 2013-11-01 to 2018-10-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 602391.